Acacia Pharma is focused on cancer supportive care – the management of the symptoms of cancer or the side effects of cancer therapy.
Patients, carers and healthcare professionals urgently need new and improved treatments in this rapidly expanding, yet poorly served area, to improve both the effectiveness of cancer treatment and the quality of life of cancer patients. Significant advances in cancer treatment in the last two decades have been made possible by progress in supportive care, according to leading professional organisation MASCC (Multinational Association of Supportive Care in Cancer www.mascc.org).
Cancer Supportive Care
Cancer supportive care is a rapidly developing clinical and commercial opportunity.
Oncologists are increasingly citing the critical importance of cancer supportive care in improving treatment outcomes and patients’ quality of life.
Acacia Pharma has generated a pipeline of product opportunities addressing a range of cancer supportive care indications, such as nausea & vomiting, xerostomia and cachexia, using a commercially driven approach to product development by identifying new uses for already marketed drugs.